Conmed strengthens board with new independent directors

Conmed ( (CNMD) ) has shared an announcement.

On May 19, 2026, CONMED’s board moved to expand its governance and leadership structure, increasing the board to nine directors and appointing industry veterans Celine Martin and Jeff Mirviss as independent non‑employee directors effective July 1, 2026, while naming Martin to the audit and strategy committees and Mirviss to the compensation and governance committees. The board also approved a new restricted stock unit framework for non‑employee directors, appointed longtime finance executive Kimberly Lockwood as interim corporate controller and principal accounting officer effective June 1, 2026, adopted updated by‑laws tightening advance‑notice rules for shareholder nominations and proposals ahead of the 2027 annual meeting, and reported that shareholders on May 18, 2026 re‑elected seven directors, backed executive pay and ratified PricewaterhouseCoopers as auditor, collectively signaling a push to strengthen board expertise, governance discipline and continuity in financial oversight.

The addition of Martin, a former senior Johnson & Johnson MedTech leader, and Mirviss, a former Boston Scientific executive, deepens CONMED’s board experience in cardiovascular, minimally invasive and peripheral intervention markets, potentially enhancing strategic direction in core growth segments. Governance changes, including revised nomination timelines and interview requirements for board candidates, along with refreshed equity compensation terms and continuity in audit oversight, may bolster the company’s control over board composition, align director incentives with long‑term performance and provide greater clarity for investors and other stakeholders on how CONMED intends to manage succession, risk and shareholder engagement.

The most recent analyst rating on (CNMD) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.

Spark’s Take on CNMD Stock

According to Spark, TipRanks’ AI Analyst, CNMD is a Neutral.

CNMD scores in the mid-range primarily due to mixed financial performance: solid cash generation and manageable leverage are offset by a sharp TTM revenue decline and compressed profitability. Technical indicators are notably bearish (below key moving averages with negative MACD), which drags the score. The latest earnings call was moderately supportive with raised organic growth guidance and maintained EPS outlook, partially balancing near-term cash flow and working-capital pressures, while valuation is neutral with a mid-to-high P/E and a modest dividend yield.

To see Spark’s full report on CNMD stock, click here.

More about Conmed

CONMED Corporation is a medical technology company that provides devices and equipment for surgical procedures across specialties such as orthopedics, general surgery, gynecology and thoracic surgery. Its products are used by surgeons and other healthcare professionals worldwide, positioning the company within the broader MedTech industry focused on minimally invasive and specialty surgical care.

Average Trading Volume: 430,229

Technical Sentiment Signal: Sell

Current Market Cap: $1.1B

Learn more about CNMD stock on TipRanks’ Stock Analysis page.